Abivertinib in patients with T790M ‐positive advanced NSCLC and its subsequent treatment with osimertinib

ConclusionsAbivertinib is a unique novel third ‐generation EGFR TKI with good tolerance and efficacy in EGFR T790M(+) NSCLC patients. For patients with progressive disease after treatment with abivertinib, osimertinib could be an option for subsequent therapy but further studies are required.Key points Abivertinib is a novel third ‐generation EGFR TKI targeting theEGFR T790M mutation Abivertinib is well tolerated and efficacious in T790M ‐positive patients Abivertinib has a unique structure, efficacy, and resistance mechanism compared with osimertinib Osimertinib treatment after AC0010 showed a good response
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research